I don't know enough about this, so any comment I might make, would be guessing. Anyone else know how this relates to the CML drugs?
You are here
Cancer diversity threatens drugs
We already know of a range of different 'types' of CML i.e. mutations - which affect some of us. At the patient day on 16 Nov, professor Jane Apperley showed a slide of approximately 25 different known CML mutations - T315i being just one of them. The good news is the matrix she showed identified which of the 5 TKIs was most effective at tackling each mutation.
As CML patients, we are fortunate to be in a position where there are several TKIs available which, assuming the side effects are tolerable, can be used to target specific mutations if they raise their ugly heads.
The gist of the future view was that we will see likely more combination therapies i.e. existing TKIs combined with other drugs which provides an even better or more targeted response.
Overall, I was surprised by the number of mutations, but reassured by the range of TKIs and their particular strengths at tackling certain mutations or 'types' of CML which affect a minority of patients.
Chris